Targeted, Non-Systemic Therapies for Gastrointestinal Diseases
THE SCIENCE
First Wave BioPharma’s product portfolio is built around its two proprietary technologies – the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, and niclosamide, an oral small molecule with anti-inflammatory properties.
LEARN MOREPIPELINE
First Wave BioPharma’s GI-disease focused programs span multiple clinical indications ranging from nutritional disorders to diseases brought on by immune malfunction. Disease targets include patient populations with digestive disorders, such as exocrine pancreatic insufficiency in cystic fibrosis patients, and inflammatory bowel diseases, including ulcerative colitis and Crohn’s disease.
IN THE NEWS
|
Jan 25, 2023
First Wave BioPharma Announces Expansion of Adrulipase Intellectual Property Portfolio
|
|
Jan 24, 2023
First Wave BioPharma to Present at Sequire Biotechnology Conference
|
|
Jan 13, 2023
First Wave BioPharma Provides Update on IND Filing For Phase 2 Trial of Enhanced Microgranule Formulation of Adrulipase for Exocrine Pancreatic Insufficiency
|
